Please assess the completion status of the following clinical trial:

Trial Title: Buprenorphine for the Treatment of Neonatal Abstinence Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 37 weeks gestation~* exposure to opiates in utero~* demonstration of signs and symptoms of neonatal abstinence syndrome requiring treatment~Exclusion Criteria:~* major congenital malformations and/or intrauterine growth retardation~* medical illness requiring intensification of medical therapy~* concomitant benzodiazepine or severe alcohol abuse, self-report of regular use of alcohol or of benzodiazepines use in the past 30 days, and/or receipt of benzodiazepines by prescription (as determined by self-report or intake urine) by the mother during pregnancy,~* concomitant use of CYP 3A inhibitors (erythromycin, clarithromycin, ketoconazole, itraconazole, HIV protease inhibitors) or inducers (rifampin, carbamazepine, phenobarbital) prior to initiation of NAS treatment~* seizure activity or other neurologic abnormality~* breast feeding~* inability of mother to give informed consent due to co-morbid psychiatric diagnosis~* hypoglycemia requiring treatment with intravenous glucose

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oral morphine solution (Type: ACTIVE_COMPARATOR): Oral morphine solution
- Buprenorphine (Type: EXPERIMENTAL): Sublingual buprenorphine

Based on this trial design, predict the completion outcome and termination type (if applicable).